Navigation Links
VirtualScopics Reports 2nd Quarter 2012 Results

ROCHESTER, N.Y., Aug. 14, 2012 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging, today reported revenues of $3,335,861 for the second quarter of 2012 compared to revenues of $3,852,925 in the second quarter of 2011. Gross profit for the quarter ended June 30, 2012 was $1,343,937 compared to $1,821,018 for the quarter ended June 30, 2011. Operating loss for the second quarter of 2012 was $166,694 compared to operating income of $158,029 in the second quarter of 2011. Earnings before interest, taxes, depreciation and amortization, and excluding stock compensation expense and gain (loss) from derivative financial instrument ("Adjusted EBITDA") for the second quarter of 2012 was $72,973 compared to $489,234 in the comparable period in 2011.

Year to date, ending June 30, 2012 results were as follows:

  • Total revenues of $7,038,019 compared to $7,511,902 for the first six months of 2011.
  • Gross profit of $2,754,850 compared to $3,420,759 in first half of 2011.
  • Adjusted EBITDA of $155,078 compared to $882,177 in the comparable period in 2011.
  • Working capital as of June 30, 2012 was $9,406,735 compared to $6,353,054 at December 31, 2011.
  • "Over the past year we have experienced a slowdown in new project awards and delays in the initiation of new studies which has impacted our top line performance," said Jeff Markin, president and chief executive officer of VirtualScopics.  He stated, "As a result, we have made and continue to make significant changes to our selling and operational processes which include the appointment of a new VP of Marketing and Business Development, the hiring of 2 new sales people covering the Western United States and Europe, along with certain procedural changes that enable our sales team significantly more face to face time with customers." He added, "Although the amount of new project awards has been slower than we experienced in previous years, we have seen an increasing number of requests for proposals throughout 2012, from both the PPD channel and our direct sales efforts.  This activity was highlighted by an important multi-study program award with a top global pharmaceutical company that recently named VirtualScopics as a preferred provider." He concluded, "We believe that the changes we are making to our sales team and our overall sales process coupled with the increases we are seeing in requests for proposals and our strategic alliance with PPD, will increase the level of business activity from what we have experienced over the past year."

    "In light of the softness in our revenues during 2012, we are continuing to actively monitor the necessary level of expenditures to support our current and anticipated business while also making the necessary investments in new market opportunities," stated Molly Henderson, chief business and financial officer of VirtualScopics. "I'm confident that our cash position will enable us to invest appropriately in both the core lab and the personalized medicine businesses." She added, "As such, we are working diligently toward the development of our personalized software applications and related FDA approval. We have initiated the hiring of personnel dedicated to this new business unit who will manage and accelerate our development in this emerging market." She concluded, "Specifically, with regard to our 510k application to the FDA, we recently submitted our responses to the examiner's questions and are confident as we near the final stages of the process."

    Jeff Markin and Molly Henderson will provide a business and second quarter 2012 financial update during the conference call this morning at 11:00 a.m. ET.  Interested participants should call 877.407.8035 when calling within the United States or +1 201 689 8035 when calling internationally. This call can also be accessed at and will be available for 30 days after the call.

    The Company provides Adjusted EBITDA as a supplemental measure to GAAP regarding the Company's operational performance. The Company defines Adjusted EBITDA as earnings less interest, taxes (if any), depreciation and amortization and further adjusted to exclude stock compensation expense and the unrealized gain (loss) on the change in fair value of derivative liabilities (mark to market adjustment for warrants).  This financial measure excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. The Company's method of calculating Adjusted EBITDA, however, may differ from methods used by other companies, and, as a result, Adjusted EBITDA measures disclosed herein may not be comparable to other similarly titled measures used by other companies. The Company continues to provide information in accordance with GAAP. However, with the adoption of ASC 815-40 and the non-cash variable nature of stock compensation expense and their very substantial impact on the overall reported net income/loss, the Company believes it is also helpful for investors to receive additional information relating more specifically to the Company's operating results. Accordingly, the Company has presented Adjusted EBITDA which excludes the non-cash effects of ASC 815-40 and ASC 718 on its financial results. Management uses Adjusted EBITDA (a) to evaluate the Company's financial performance, (b) to set internal spending budgets, and (c) to measure operational profitability. In addition, investors have requested these non-GAAP financial measures as a means of providing consistent and comparable information with past reports of financial results. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure, net (loss)/income.

    About VirtualScopics, Inc.
    VirtualScopics, Inc. is a leading provider of quantitative imaging solutions to accelerate drug and medical device development in addition to improving patient care.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit

    Forward-Looking Statements
    The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

    -Financial tables to follow-CONTACT: Investor Relations:Company Contact:Tim Ryan

    Molly HendersonThe Shoreham Group 

    Chief Business and Financial Officer, Sr. Vice President80 Eighth Ave, Ste 1107

    500 Linden OaksNew York, NY 10011

    Rochester, New York 14625+1 212 242.7777 Direct

    +1 585   

     VirtualScopics, Inc. and SubsidiaryCondensed Consolidated Statements of Operations (unaudited)For the Three Months Ended June 30,For the Six Months Ended June 30,2012201120122011Revenues$
    ,925,863Reimbursement revenues237,545276,672646,045586,039Total revenues3,335,8613,852,9257,038,0197,511,902Cost of revenues1,754,3791,755,2353,637,1243,505,104Cost of reimbursement revenues237,545276,672646,045586,039Total cost of services1,991,9242,031,9074,283,1694,091,143Gross profit1,343,9371,821,0182,754,8503,420,759Operating expensesResearch and development357,839350,449714,166664,706Sales and marketing311,393307,618642,465609,714General and administrative615,159687,9691,269,8991,288,181Stock-based compensation expense119,249203,729295,185437,934Depreciation and amortization106,991113,224218,610250,448Total operating expenses1,510,6311,662,9893,140,3253,250,983Operating (loss) income (166,694)158,029(385,475)169,776Other income (expense)Interest income71513,0061,13014,232Other expense(5,446)(16,720)(5,713)(17,940)Unrealized gain (loss) on change in   fair value of derivative liabilities108,459173,335(286,453)(38,799)Total other income (expense)103,728169,621(291,036)(42,507)Net (loss) income(62,966)327,650(676,511)127,269Preferred stock deemed dividend1,806,919-1,806,919-Preferred stock dividends41,33312,00053,33324,989Net (loss) income attributable to common stockholders$
    2,280Basic and diluted net (loss) income per common share$
    .00Weighted average number of common shares outstandingbasic 29,706,07429,045,42829,538,38128,544,856diluted29,706,07436,964,76029,538,38136,738,762*

    Cost of revenues includes non-cash stock-based compensation expense of $13,427 and $14,252 for thethree months ended June 30, 2012 and 2011, respectively and $26,758 and $24,019 for the six months ended June 30, 2012 and 2011, respectively. 

     VirtualScopics, Inc. and SubsidiaryCondensed Consolidated Balance SheetsJune 30,December 31,20122011Assets(unaudited)Current assets  Cash 

    7,778,559$   5,737,009  Accounts receivable, net

    2,823,9562,435,496  Prepaid expenses and other current assets

    378,923361,376Total current assets

    10,981,4388,533,881Patents, net

    1,525,8211,582,938Property and equipment, net

    468,001514,230Other assets

    16,28327,140Total assets

    2,991,543$ 10,658,189Liabilities and Stockholders' EquityCurrent liabilities  Accounts payable and accrued expenses

    843,275  Accrued payroll

    600,231759,470  Unearned revenue

    Derivative liabilities

    37,816156,596Total current liabilities

    1,574,7032,180,827Commitments and Contingencies

    --Stockholders' EquityConvertible preferred stock, $0.001 par value; 15,000,000 shares authorized; Series A 8,400 shares authorized; issued and outstanding, 2,190 at June 30, 2012 and December 31, 2011; liquidation preference $1,000 per share

    22Series B 6,000 shares authorized; issued and outstanding, 600 at June 30, 2012 and December 31, 2011; liquidation preference $1,000 per share

    11Series C-1 3,000 shares authorized; issued and outstanding, 3,000 and 0 shares at June 30, 2012 and December 31, 2011, respectively; liquidation preference $1,000 per share

    3-Series C-2 3,000 shares authorized; issued and outstanding, 0 shares at June 30, 2012 and December 31, 2011; liquidation preference $1,000 per share

    --Common Stock, $0.001 par value; 85,000,000 shares authorized; issued and outstanding, 29,747,762 and 29,370,687 shares at June 30, 2012 and December 31, 2011, respectively 

    29,74829,371Additional paid-in capital

    21,498,54517,882,936Accumulated deficit

    (10,111,459)(9,434,948)Total stockholders' equity

    11,416,8408,477,362Total liabilities and stockholders' equity

    2,991,543$ 10,658,189 


     Three Months EndedThree Months EndedAdjusted EBITDA (non-GAAP measurement):June 30, 2012June 30, 2011(unaudited)(unaudited)Net (loss) income$

    327,650Interest income and other expenses4,731

    3,714Depreciation and amortization106,991

    113,224Stock-based compensation expense 132,676

    217,981Unrealized gain on change in fair value of derivative liabilities(108,459)

    (173,335)  Adjusted EBITDA$

    489,234  Basic Adjusted EBITDA per common share, non-GAAP$

    .02  Diluted Adjusted EBITDA per common share, non-GAAP$

    .01Six Months EndedSix Months EndedAdjusted EBITDA (non-GAAP measurement):June 30, 2012June 30, 2011(unaudited)(unaudited)Net (loss) income$

    27,269Interest income and other expenses4,583

    3,708Depreciation and amortization218,610

    250,448Stock-based compensation expense 321,943

    461,953Unrealized loss on change in fair value of derivative liabilities286,453

    38,799  Adjusted EBITDA$

    882,177  Basic Adjusted EBITDA per common share, non-GAAP$

    .03  Diluted Adjusted EBITDA per common share, non-GAAP$


    SOURCE VirtualScopics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. VirtualScopics Schedules Second Quarter 2012 Earnings Announcement
    2. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    3. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    4. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    5. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    6. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    7. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    8. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    9. Luminex Corporation Reports First Quarter 2012 Results
    10. Hospira Reports First-Quarter 2012 Results
    11. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
    Post Your Comments:
    (Date:10/9/2015)... October 9, 2015 ... sich einer Kolonoskopie im Rahmen eines Screenings, ... Die NOCT-Studie bewertete auch die Compliance, Sicherheit, ... ® ) an erwachsenen Patienten vergleicht, ... Screenings, einer beobachtenden oder einer diagnostischen Kolonoskopie ...
    (Date:10/9/2015)... -- --> --> ... of an Intellectual Property & Subsidiary Assignment and an Assignment & Assumption ... Corporation, related party, and a majority holder of 88% ... --> These agreements were executed as part of ... and Development components shall now be separate from the ...
    (Date:10/9/2015)... India , October 9, 2015 ... --> The report ... market and overall status of the ... of guidance and direction for companies ... . ...
    Breaking Medicine Technology:
    ... /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and ... Shareholder Meeting to the 26th floor, Conference Room E ... (EDT). Shareholders will be admitted beginning at 9:30 am. ...
    ... 2011 Bacterin International Holdings, Inc. (NYSE Amex: ... that it has scheduled a conference call ... to discuss the Company,s financial results for its fourth ...   Bacterin International Holdings, Inc. intends to issue its earnings ...
    Cached Medicine Technology:
    (Date:10/9/2015)... ... 09, 2015 , ... The American Osteopathic Foundation (AOF) has ... Education J. Michael Finley, DO, as the recipient of the 2015 W. Douglas ... on graduate medical education opportunities for osteopathic residents, and his dedication to promoting ...
    (Date:10/9/2015)... ... October 09, 2015 , ... A new health tool that helps identify ... available online ( ) – just in time for the cold and flu ... October. However, for many in the U.S., the real start of cold/flu season is ...
    (Date:10/9/2015)... ... October 09, 2015 , ... ... promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. This alternative ... invisible against the teeth, which allow patients to complete treatment in privacy. Additionally, ...
    (Date:10/9/2015)... Washington, DC (PRWEB) , ... October 09, 2015 , ... ... agreement from the US Centers for Disease Control and Prevention (CDC) to improve the ... 14 years that AAFA has been awarded a project by the CDC and allows ...
    (Date:10/9/2015)... Ohio (PRWEB) , ... October 09, 2015 , ... ... United States, is welcoming individuals from all walks of life to save money ... the set price of $25 per month per medication, individuals and families can ...
    Breaking Medicine News(10 mins):
    ... 12 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... on February 19, 2009, and will host a conference call to ... Eastern Time. , , , Date: ... Time, Conference call access:, Internet: ...
    ... Pamper Tired TootsiesBETHESDA, Md., Feb. 12 Valentine,s Day marks ... men and women. While the old adage "a way to ... true, another body part is gaining affection from both sexes ... (APMA) survey revealed 84 percent of women are embarrassed about ...
    ... MediCom Worldwide, Inc., an accredited provider of continuing medical ... of an online repository of resources and education on ... of health care practitioners.The goal of Managing ... to provide an extensive array of programs to support ...
    ... Scientists studying an inherited condition resulting in blindness and ... affect both eye function and normal tooth development. ... the formation of teeth and eyes has been uncovered ... in two families living in a village in the ...
    ... a key role in the prevention and treatment of ... Endothelial cells line the blood vessels and are critical ... , Researchers at the Centenary Institute have discovered ... cells. , Professor Jenny Gamble, Head of ...
    ... research will focus increasingly on electronic data, with less ... long term trend emerged at a recent conference on ... dealt with the challenges posed by the growing scale ... But in the more immediate future biological specimens will ...
    Cached Medicine News:
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: